Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.000
-0.010 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?
↗
May 25, 2026
The stock looks cheap, but appearances can be deceiving.
Via
The Motley Fool
Topics
Artificial Intelligence
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
↗
May 19, 2026
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Regulatory Compliance
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
May 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss
↗
May 06, 2026
Via
Chartmill
Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat
↗
February 25, 2026
Via
Chartmill
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
3 Stocks Poised to Disrupt the Healthcare Market by 2030
↗
May 08, 2026
The old healthcare model is breaking down.
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion (RXRX) Q1 2026 Earnings Transcript
↗
May 07, 2026
Recursion (RXRX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
From
BioMedWire
Via
GlobeNewswire
Recursion Reports First Quarter Financial Results and Provides Business Update
May 06, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Board Transition
April 30, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
April 29, 2026
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
April 07, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
April 06, 2026
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...
Via
MarketMinute
Topics
Artificial Intelligence
1 Beaten-Down AI Stock to Buy and 1 to Avoid
↗
April 01, 2026
One of these is not like the other.
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
March 31, 2026
From
Citeline
Via
GlobeNewswire
2 AI Healthcare Stocks to Buy Right Now
↗
March 31, 2026
The convergence of two already fantastic industries is creating an incredible opportunity.
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
March 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026
↗
March 22, 2026
The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery.
Via
The Motley Fool
Topics
Artificial Intelligence
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
↗
March 21, 2026
AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.
Via
The Motley Fool
Topics
Artificial Intelligence
Can This AI Stock Bounce Back in 2026?
↗
March 08, 2026
It's not looking too good for the biotech.
Via
The Motley Fool
Topics
Animal Testing
Artificial Intelligence
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
February 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Recursion (RXRX) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Recursion (RXRX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
What's Behind The Jump In Recursion Pharmaceuticals Stock?
↗
February 25, 2026
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.
Via
Benzinga
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’
↗
February 25, 2026
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.
Via
Stocktwits
Topics
Artificial Intelligence
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
February 23, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
February 23, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
February 22, 2026
Ark Invest added to three positions that are well below last year's highs.
Via
The Motley Fool
Topics
Artificial Intelligence
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges
↗
February 19, 2026
Via
MarketBeat
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.